400-0512-686

Retinol-binding protein assay kit (latex enhanced immune nephelometry)

For in vitro quantitative determination of serum retinol binding protein content

【Clinical significance】

Retinol binding protein (RBP) is mainly synthesized in the liver, and serum RBP can be affected by changes in liver disease. Liver disease, cirrhosis and acute and chronic hepatitis can significantly lower serum RBP. When glomerular filtration is dysfunctional, serum RBP concentration will increase. Besides, RBP will increase significantly in the urine when renal tubular injured, which can be used as an early diagnostic marker of renal tubular injury.

【Test principle】

Mix serum (containing RBP) and reagent (goat anti-human polyclonal antibody-sensitized RBP nanospheres) to form insoluble immune complexes, which increases the turbidity of reaction solution.
Measure absorbance by spectrophotometer at the wavelength of 600nm
The turbidity reflects the concentration of RBP in the sample, which can be read out by a working curve calibrated by standard serum.

【Storage conditions and validity】

Stable for one year when stored at 2 ~ 8 ℃ in the dark (freeze prohibited),
Stable at 2~8 °C for one month after initial use.

【Note】

1. The amount of reagent and sample might need to increase or decrease under the same proportion to meet the requirement of biochemical analytical instruments.
2. When the samples β2-MG concentration exceeds 150.0mg/L, dilute with 0.9% saline for a maximum of 10 times and test again.
3. 0.05% Proclin-300 is contained as a preservative. NO SWALLOW and avoid contact with skin and mucous membranes. If you accidentally contact with skin or mucous membranes, rinse immediately with plenty of water and go to hospital for treatment.
4. Sheep-derived antibodies are included, which is a potential risk of infection. NO SWALLOW and avoid contact with skin and mucous membranes.




Top

Earlier
April 2014

Lumigenex receives CFDA approval for four POCT immunoassay kits to help physicians quickly and accurately diagnose heart diseases.

March 2014

Lumigenex receives CFDA approval for five immunoassay reagents adaptable to most chemical analyzers.

February 2014

Lumigenex received CFDA approval for time-resolved fluorescence immunochromatographic analyzer.

January 2014

Dr. He Aimin was named "National Thousand Talents Program"

December 2013

Lumigenex access to "high-tech enterprises in Jiangsu Province" title.

September 2013

Lumigenex passed The first Food and Drug Administration by the Suzhou Municipal Quality Management System Assessment.